Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sexual dimorphic evolution of metabolic programming in non-genetic non-alimentary mild metabolic syndrome model in mice depends on feed-back mechanisms integrity for pro-opiomelanocortin-derived endogenous substances.
Loizzo S, Vella S, Loizzo A, Fortuna A, Di Biase A, Salvati S, Frajese GV, Agrapart V, Ramirez Morales R, Spampinato S, Campana G, Capasso A, Galietta G, Guarino I, Carta S, Carru C, Zinellu A, Ghirlanda G, Seghieri G, Renzi P, Franconi F. Loizzo S, et al. Among authors: agrapart v. Peptides. 2010 Aug;31(8):1598-605. doi: 10.1016/j.peptides.2010.05.006. Epub 2010 May 20. Peptides. 2010. PMID: 20493223
Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial.
Bonneville-Levard A, Frappaz D, Tredan O, Lavergne E, Corset V, Agrapart V, Chabaud S, Pissaloux D, Wang Q, Attignon V, Cartalat S, Ducray F, Thomas-Maisonneuve L, Honnorat J, Meyronet D, Taillandier L, Blonski M, Viari A, Baudet C, Sohier E, Lantuejoul S, Paindavoine S, Treilleux I, Rodriguez C, Pérol D, Blay JY. Bonneville-Levard A, et al. Among authors: agrapart v. Med Oncol. 2021 Nov 5;39(1):4. doi: 10.1007/s12032-021-01536-4. Med Oncol. 2021. PMID: 34739635
Tumor Molecular Profiling: Pediatric Results of the ProfiLER Study.
Benezech S, Saintigny P, Attignon V, Pissaloux D, Paindavoine S, Faure-Conter C, Corradini N, Marec-Berard P, Bergeron C, Cassier P, Eberst L, Dufresne A, Wang Q, Agrapart V, De La Fouchardière A, Perol D, Garin G, Corset V, Ben Abdesselem L, Chabaud S, Tredan O, Blay JY, Frappaz D. Benezech S, et al. Among authors: agrapart v. JCO Precis Oncol. 2020 Nov;4:785-795. doi: 10.1200/PO.20.00023. JCO Precis Oncol. 2020. PMID: 35050753
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Trédan O, Wang Q, Pissaloux D, Cassier P, de la Fouchardière A, Fayette J, Desseigne F, Ray-Coquard I, de la Fouchardière C, Frappaz D, Heudel PE, Bonneville-Levard A, Fléchon A, Sarabi M, Guibert P, Bachelot T, Pérol M, You B, Bonnin N, Collard O, Leyronnas C, Attignon V, Baudet C, Sohier E, Villemin JP, Viari A, Boyault S, Lantuejoul S, Paindavoine S, Treillleux I, Rodriguez C, Agrapart V, Corset V, Garin G, Chabaud S, Pérol D, Blay JY; ProfiLER investigators. Trédan O, et al. Among authors: agrapart v. Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080. Ann Oncol. 2019. PMID: 30865223 Free article.
A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat MJ, Poirot C, Dubois F, Xuereb L, Bossard CJ, Guigal-Stephan N, Lockhart B, Andre F. Campone M, et al. Among authors: agrapart v. Cancer Chemother Pharmacol. 2019 Apr;83(4):743-753. doi: 10.1007/s00280-018-03765-3. Epub 2019 Jan 25. Cancer Chemother Pharmacol. 2019. PMID: 30684019 Clinical Trial.
Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
Bernichon E, Vallard A, Wang Q, Attignon V, Pissaloux D, Bachelot T, Heudel PE, Ray-Coquard I, Bonnet E, de la Fouchardière A, Faure C, Chopin N, Beurrier F, Racadot S, Sunyach MP, Rancoule C, Perol D, Corset V, Agrapart V, Tinquaut F, Blay JY, Magné N, Trédan O. Bernichon E, et al. Among authors: agrapart v. Ann Oncol. 2017 Nov 1;28(11):2773-2779. doi: 10.1093/annonc/mdx488. Ann Oncol. 2017. PMID: 28945826 Free article.
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
Awada A, Dirix L, Manso Sanchez L, Xu B, Luu T, Diéras V, Hershman DL, Agrapart V, Ananthakrishnan R, Staroslawska E. Awada A, et al. Among authors: agrapart v. Ann Oncol. 2013 Jan;24(1):109-16. doi: 10.1093/annonc/mds284. Epub 2012 Sep 11. Ann Oncol. 2013. PMID: 22967996 Free article. Clinical Trial.